Zealand Pharma finds all patients for phase III study

A total of 108 patients have been enrolled in Zealand Pharma's crucial trial of glepaglutide as a treatment of short bowel syndrome.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

Biotech company Zealand Pharma has recruited all 108 patients required for a phase III study of its drug candidate glepaglutide, which is meant to treat short bowel syndrome, the company announces in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading